Terms: = Ovarian cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Prognosis
4 results:
1. High serum levels of inflammatory markers are associated with early recurrence in patients with high-grade serous ovarian cancer after platinum therapy.
Brzezinska B; Mysona DP; Richardson KP; Rungruang B; Hopkins D; Bearden G; Higgins R; Johnson M; Satter KB; McIndoe R; Ghamande S; Purohit S
Gynecol Oncol; 2023 Dec; 179():1-8. PubMed ID: 37862814
[TBL] [Abstract] [Full Text] [Related]
2. Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis.
Assis J; Pereira C; Nogueira A; Pereira D; Carreira R; Medeiros R
Cancer Treat Rev; 2017 Dec; 61():35-52. PubMed ID: 29100168
[TBL] [Abstract] [Full Text] [Related]
3. Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities.
Li L; Bai H; Yang J; Cao D; Shen K
Oncotarget; 2017 Feb; 8(9):15136-15148. PubMed ID: 28122348
[TBL] [Abstract] [Full Text] [Related]
4. WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis.
Paige AJ; Zucknick M; Janczar S; Paul J; Mein CA; Taylor KJ; Stewart M; Gourley C; Richardson S; Perren T; Ganesan TS; Smyth JF; Brown R; Gabra H
Eur J Cancer; 2010 Mar; 46(4):818-25. PubMed ID: 20074932
[TBL] [Abstract] [Full Text] [Related]
